A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)

Sponsor
H. Lundbeck A/S
Study ID
NCT07513441
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
35 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Lu AF28996 — DRUG
    Capsule administered orally per schedule specified in the arm description.

Study Details

The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.

Key Dates

First listed
Apr 7, 2026
Start date
Mar 31, 2026
Status verified
Mar 2026
Primary completion
May 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Lu AF28996
    Participants will receive oral doses of Lu AF28996 twice daily (BID) as add-on to the participant's usual PD treatment (levodopa and allowed PD medications) during the Up-titration treatment period, whereafter the participants will initiate down-titration of Lu AF28996.

Primary Outcome Measure

Number of Participants With Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Up to 60 days ]

Central Contacts

Find similar trials

Nationwide
Parkinson's disease trialsNeurology trialsBrain disorders trials

Related Studies